Alemtuzumab: Effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sézary syndrome

European Journal of Haematology

Volumn 73, Issue 6, 2004, Pages 447-449

  Gibbs, Simon D J ^a   Herbert, Kirsten E ^a   McCormack, Christopher ^b   Seymour, John F ^a   Prince, H Miles ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Alemtuzumab; Chronic lymphocytic leukaemia; Pancytopenia; Sezary syndrome

Indexed keywords

ALEMTUZUMAB; COTRIMOXAZOLE; FLUCONAZOLE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; MEROPENEM; VALACICLOVIR; VANCOMYCIN;

AGED; ARTICLE; B CELL LEUKEMIA; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CUTANEOUS T CELL LYMPHOMA; CYTOMEGALOVIRUS; DISEASE COURSE; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; INFECTION; LEUKOCYTE COUNT; MALE; MONOTHERAPY; MORBIDITY; NEUTROPHIL; PANCYTOPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; SEZARY SYNDROME; TREATMENT OUTCOME; VIRUS LOAD;

ABSIDIA; AGED; ANTI-INFECTIVE AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ASPERGILLOSIS; CELLULITIS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOCOMPROMISED HOST; LEUKEMIA, B-CELL, CHRONIC; MALE; MUCORMYCOSIS; NEOPLASMS, MULTIPLE PRIMARY; PANCYTOPENIA; REMISSION INDUCTION; SEZARY SYNDROME; SINUSITIS;

EID: 9444243841     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00332.x     Document Type: Article

References (12)

1. VOLK AL. VANNUCCI SA, COOK W, et al. Composite mycosis fungoides and B-cell chronic lymphocytic leukemia. Ann Diagn Pathol 2002;6:172-182.
2. BOLLI N, DI IANNI M, SIMONETTI S, et al. Treating two concurrent B-cell and T-cell lymphoid neoplasms with alemtuzumab monotherapy. Lancet Oncol 2004;5:64-65.
3. HULL PR, SAXENA A. Mycosis fungoides and chronic lymphoblastic leukemia - composite T-cell and B-cell lymphomas presenting in the skin. Br J Dermatol 2000;143:439-444.
4. PANGALIS GA, DIMOPOULOU MN, ANGELOPOULOU MK, TSEKOURAS C, VASSILAKOPOULOS TP, VAIOPOULOS G, SIAKANTARIS MP, Campath-1H (anti-CD 52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol 2001;18:99-107.
5. ENBLAD G, HAGBERG H, ERLANSON M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103:2920-2924.
6. KENNEDY GA, SEYMOUR JF, WOLF M, et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol 2003;4:250-256.
7. HERBERT KE, PRINCE HM, WESTERMAN DA. Pure red-cell aplasia due to parvovirus B19 infection in a patient treated with alemtuzumab. Blood 2003;101:1654.
8. LENIHAN DJ, ALENCAR AJ, YANG D, KURZROCK R, KEATING MJ, DUVIC M. Cardiac toxicity of alemtuzumab in patients with mycosis fingoides/Sezary syndrome. Blood 2004;104:655-658.
9. KEATING M, et al. Management guidelines for use of alemtuzumab in B-chronic lymphocytic leukemia. Clin Lymphoma 2004;4:220-227.
10. RIEGER K. et al. Efficacy and tolerability of Alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia - change of regimen needed? Leuk Lymphoma 2004;45:345-349.
11. MONTILLO M, CAFRO AM, TEDESCHI A, BRANDO B, ORESTE P, VERONESE S, ROSSI V, CAIROLI R, PUNGOLINO E, MORRA E. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding tofludarabine. Haematologica 2002;87:695-700.
12. GUVEN H, et al. Expansion of natural killer (NK) and natural killer-like T (NKT) cell populations derived from patients with chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Leukemia 2003;17:1945-1947.